UPDATE: Wunderlich Securities Initiates Coverage on Cardiovascular Systems with Buy Rating, $24 PT on Positive Outlook

In a report published Friday, Wunderlich Securities analyst James Terwilliger initiated coverage on Cardiovascular Systems CSII with a Buy rating and $24.00 price target. In the report, Wunderlich Securities noted, “We are initiating coverage of Cardiovascular Systems, Inc. (CSII) with a Buy rating and a 12-month price target of $24.00, or 4.0x our fiscal 2015 revenue per share estimate of $6.08. CSII is a medical device company focused on minimally invasive treatments for vascular disease. CSII's initial focus is on the treatment of peripheral artery disease (PAD). CSII's products are catheter-based systems capable of treating a range of plaque types in leg arteries both above and below the knee. CSII intends to expand its catheter-based systems and move into the interventional coronary market. CSII has already sent its PMA application to the FDA to treat coronary artery disease. We assume regulatory approval and a coronary product launch in the U.S. in Q114.” Cardiovascular Systems closed on Thursday at $20.79.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst RatingsJames TerwilligerWunderlich Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!